A production process of thermoplastic polyurethane material for medical use

By grafting heparin and modified barium sulfate in polyurethane materials, the problem of polyurethane materials causing inflammation and coagulation in the human body is solved, the antibacterial performance is improved, and the multiple clinical performance needs of the material are met.

CN118388790BActive Publication Date: 2024-11-12ADVANCED THERMOPLASTIC POLYMER TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410675871.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-29
Publication Date
2024-11-12
Estimated Expiration
2044-05-29

AI Technical Summary

Technical Problem

Existing polyurethane materials are prone to induce inflammatory reactions, coagulation and bacterial infections after implantation in the human body, and are insufficient in antioxidant and antibacterial properties, which cannot fully meet clinical needs.

Method used

A production process is used to prepare thermoplastic polyurethane materials for medical use, by synthesizing polycarbonate polyurethanes with carboxyl groups, and grafting heparin on its surface to improve anticoagulant performance, while introducing modified barium sulfate to enhance antibacterial properties.

Benefits of technology

It significantly improves the anticoagulant and antibacterial properties of the material, reduces the risk of inflammatory response and bacterial infection, and enhances durability and antioxidant properties in complex water environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004864035920000131
    Figure BDA0004864035920000131
Patent Text Reader

Abstract

The invention discloses a production process of a thermoplastic polyurethane material for medical use, belonging to the technical field of medical materials. A polyurethane resin is first prepared, which is a polycarbonate polyurethane with a carboxyl group. The carboxyl group is introduced while the excellent performance of the polycarbonate polyurethane itself is brought into play. Under the action of 4-dimethylaminopyridine and diisopropylcarbodiimide, the carboxyl group can react with the hydroxyl group on the heparin structure and then the heparin can be grafted on the surface of the material, thereby giving the polyurethane material an anticoagulant effect. Compared with the existing coating method of free heparin, the present invention grafts heparin in a chemically bonded manner, so that the heparin structure is more firmly combined with the polyurethane material, and the initial contact activation of thrombin can be hindered through the antithrombin III-mediated pathway, thereby having better anticoagulant performance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical materials, and in particular relates to a production process of a thermoplastic polyurethane material for medical use. Background Art

[0002] With the development of medicine, materials science, biology, chemistry and other disciplines, medical polymer materials have been widely used in the biomedical field. First, polymer materials have excellent mechanical properties and chemical stability, which are very suitable for medical use. Secondly, polymer materials are widely available and inexpensive, making them suitable for making disposable medical supplies, avoiding the problems of disinfection and cross-infection caused by the repeated use of traditional materials due to their high prices.

[0003] Polyurethane (PU) has long been used in the production of medical catheter materials. It has stable chemical properties and good biocompatibility such as low toxicity and no teratogenicity. At the same time, polyurethane materials have good physical properties, are easy to process, and have excellent product quality. Therefore, they are widely used in the medical field and can maintain long-term stability when implanted in the human body. They can also be used in the production of indwelling needles. However, although polyurethane has certain tissue compatibility and blood compatibility, it still cannot fully meet the requirements of practical clinical applications. For example, long-term implantation of polyurethane medical products in the body is likely to cause an inflammatory response in the body, and direct contact with blood will inevitably produce varying degrees of coagulation. In addition, polyurethane medical insertions or implanted products may also be accompanied by bacterial infections, body damage, and other problems. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a production process of a thermoplastic polyurethane material for medical use.

[0005] The purpose of the present invention can be achieved through the following technical solutions:

[0006] A production process of a thermoplastic polyurethane material for medical use comprises the following steps:

[0007] The first step is to add polyhexamethylene carbonate diol into a flask, introduce nitrogen, heat to 75°C and stir at a uniform speed until it melts, add isophorone diisocyanate, keep warm and stir magnetically for 3 hours to obtain a prepolymer, then add dimethyl carbonate to reduce the viscosity, continue stirring and react for 1 hour, cool to 60°C, add dibutyltin dilaurate and 2,2-bis(hydroxymethyl)propionic acid, continue stirring and react for 3 hours to obtain a polyurethane resin, and control the amount ratio of polyhexamethylene carbonate diol, isophorone diisocyanate, dimethyl carbonate and 2,2-bis(hydroxymethyl)propionic acid to be 10-15g:4-5mL:25-30mL:1.5-2mL, and the amount of dibutyltin dilaurate is 0.1-0.3% of the weight of polyhexamethylene carbonate diol;

[0008] In the first step, polyhexamethylene carbonate diol is used as the soft segment, isophorone diisocyanate is used as the hard end, and 2,2-bis(hydroxymethyl)propionic acid is used as the chain extender. Under the action of the catalyst dibutyltin dilaurate, a polycarbonate type polyurethane is prepared. The hydrogen bonding between the polycarbonate and the hard segment is strong and the degree of crystallization is large, so the polycarbonate type polyurethane has better hydrolysis resistance. Moreover, compared with the existing polyether type polyurethane, the conjugation effect and molecular chain rigidity of the carbonate group are stronger than the ether group, so the antioxidant property is better, which can prevent the complex water environment in the human body from causing the uncontrollable hydrolysis of the thermoplastic polyurethane molecular chain to release H + , enzymes and free radicals in the body, and introduces a carboxyl structure to facilitate the next grafting reaction;

[0009] The second step is to mix the prepared polyurethane resin and modified barium sulfate and send them into a twin-screw extruder for extrusion and granulation to obtain a sample. The screw speed is controlled to be 100r / min, the extrusion temperature is 195°C, and the weight ratio of the polyurethane resin to the modified barium sulfate is 4-5:1;

[0010] The third step is to add the prepared sample into tetrahydrofuran, stir at a uniform speed and add heparin, stir for 15 minutes, add 4-dimethylaminopyridine and diisopropylcarbodiimide, stir for 4 hours in an ice-water bath, transfer to room temperature and continue stirring for 4 hours, filter, and vacuum dry to obtain a medical thermoplastic polyurethane material, and control the weight ratio of the sample, heparin, 4-dimethylaminopyridine, diisopropylcarbodiimide and tetrahydrofuran to be 10-20:1:0.1-0.2:0.3-0.5:20-30.

[0011] In the third step, under the action of 4-dimethylaminopyridine and diisopropylcarbodiimide, the carboxyl groups introduced into the sample can react with the hydroxyl groups on the heparin structure and thus graft the heparin onto the surface of the material.

[0012] Furthermore, the modified barium sulfate is prepared by the following steps:

[0013] Step S1, adding barium carbonate to deionized water, stirring magnetically at 45°C and adding sodium sulfate, stirring magnetically for 30 minutes, slowly adding an aqueous solution of polyethyleneimide, stirring evenly and transferring to a reactor, heating to 150°C, and keeping the temperature for reaction for 10 hours. After the reaction is completed, filtering, washing with deionized water and anhydrous ethanol three times respectively, and drying to obtain pretreated barium sulfate, controlling the weight ratio of barium carbonate, polyethyleneimide and deionized water to be 4.58-5.02g:0.144g:50mL, and the molar ratio of barium carbonate to sodium sulfate to be 1:1;

[0014] The aqueous solution of polyethyleneimide is prepared by mixing polyethyleneimide and deionized water in a dosage ratio of 0.144 g:10 mL.

[0015] In step S1, barium carbonate and sodium sulfate react to generate barium sulfate precipitate, and polyethyleneimine is added to obtain pretreated barium sulfate, which is polyethyleneimine barium sulfate;

[0016] Step S2, dispersing the obtained pretreated barium sulfate in anhydrous ethanol, adding hexyl bromide, stirring magnetically and reacting for 12 hours at room temperature, adding methyl iodide and continuing the reaction for 12 hours, washing with deionized water and anhydrous ethanol three times respectively after the reaction, drying at 55° C. to obtain modified barium sulfate, controlling the weight ratio of the pretreated barium sulfate, hexyl bromide and anhydrous ethanol to be 1:10:50, and the molar ratio of methyl iodide and hexyl bromide to be 1:1.

[0017] Polyethylenimide barium sulfate carries a large number of amino groups. Through alkylation modification with hexyl bromide, some of the amino groups can be converted into quaternary ammonium salts, and then the quaternary ammonium salt structure is connected to the barium sulfate, giving the barium sulfate antibacterial properties, thereby giving the matrix excellent antibacterial properties, and the unreacted amino groups can also react with the carboxyl groups on heparin, thereby increasing the grafting rate of heparin to the matrix.

[0018] Beneficial effects of the present invention:

[0019] The present invention prepares a medical thermoplastic polyurethane material. A polycarbonate polyurethane with a carboxyl group is first synthesized, and the carboxyl group is introduced while the excellent performance of the polycarbonate polyurethane itself is brought into play. Under the action of 4-dimethylaminopyridine and diisopropylcarbodiimide, the carboxyl group can react with the hydroxyl group on the heparin structure and then the heparin can be grafted on the surface of the material, thereby giving the polyurethane material an anticoagulant effect. Compared with the existing coating method of free heparin, the present application grafts heparin in a chemically bonded manner, so that the heparin structure is more firmly combined with the polyurethane material, and the initial contact activation of thrombin can be hindered through the antithrombin III-mediated pathway, so that the polyurethane material has better anticoagulant performance.

[0020] In addition, the present invention further adds modified barium sulfate to the polyurethane material, which can exert the imaging function of barium sulfate on the one hand, and give the barium sulfate antibacterial properties after modification with quaternary ammonium salt, thereby giving the matrix excellent antibacterial properties, preventing bacteria from adhering to the surface of the material, causing bacterial infection in the human body and causing body damage. Moreover, the unreacted amino group in the barium sulfate modified with quaternary ammonium salt can also react with the carboxyl group on heparin, further improving the grafting rate of heparin and the matrix, and improving the binding performance of heparin and the matrix. DETAILED DESCRIPTION

[0021] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0022] Example 1

[0023] A production process of a thermoplastic polyurethane material for medical use comprises the following steps:

[0024] The first step is to add polyhexamethylene carbonate diol into a flask, introduce nitrogen, heat to 75°C and stir at a uniform speed until it melts, add isophorone diisocyanate, keep warm and stir magnetically for 3 hours to obtain a prepolymer, then add dimethyl carbonate to reduce the viscosity, continue stirring and react for 1 hour, cool to 60°C, add dibutyltin dilaurate and 2,2-bis(hydroxymethyl)propionic acid, continue stirring and react for 3 hours to obtain a polyurethane resin, and control the amount ratio of polyhexamethylene carbonate diol, isophorone diisocyanate, dimethyl carbonate and 2,2-bis(hydroxymethyl)propionic acid to be 10g:4mL:25mL:1.5mL, and the amount of dibutyltin dilaurate is 0.1% of the weight of polyhexamethylene carbonate diol;

[0025] The second step is to mix the prepared polyurethane resin and modified barium sulfate and send them into a twin-screw extruder for extrusion and granulation to obtain a sample. The screw speed is controlled to be 100r / min, the extrusion temperature is 195°C, and the weight ratio of the polyurethane resin to the modified barium sulfate is 4:1;

[0026] The third step is to add the prepared sample into tetrahydrofuran, stir at a uniform speed and add heparin, stir for 15 minutes, add 4-dimethylaminopyridine and diisopropylcarbodiimide, stir for 4 hours in an ice-water bath, transfer to room temperature and continue stirring for 4 hours, filter, and vacuum dry to obtain a medical thermoplastic polyurethane material, and control the weight ratio of the sample, heparin, 4-dimethylaminopyridine, diisopropylcarbodiimide and tetrahydrofuran to be 10:1:0.1:0.3:20.

[0027] The modified barium sulfate comprises the following steps:

[0028] Step S1, adding barium carbonate to deionized water, stirring magnetically at 45°C and adding sodium sulfate, stirring magnetically for 30 minutes, slowly adding an aqueous solution of polyethyleneimide, stirring evenly and transferring to a reactor, heating to 150°C, and keeping the temperature for 10 hours. After the reaction is completed, filtering, washing with deionized water and anhydrous ethanol three times respectively, and drying to obtain pretreated barium sulfate, controlling the weight ratio of barium carbonate, polyethyleneimide and deionized water to be 4.58g:0.144g:50mL, and the molar ratio of barium carbonate to sodium sulfate to be 1:1;

[0029] The aqueous solution of polyethyleneimide is prepared by mixing polyethyleneimide and deionized water in a dosage ratio of 0.144 g:10 mL.

[0030] Step S2, dispersing the obtained pretreated barium sulfate in anhydrous ethanol, adding hexyl bromide, stirring magnetically and reacting for 12 hours at room temperature, adding methyl iodide and continuing the reaction for 12 hours, washing with deionized water and anhydrous ethanol three times respectively after the reaction, drying at 55° C. to obtain modified barium sulfate, controlling the weight ratio of the pretreated barium sulfate, hexyl bromide and anhydrous ethanol to be 1:10:50, and the molar ratio of methyl iodide and hexyl bromide to be 1:1.

[0031] Example 2

[0032] A production process of a thermoplastic polyurethane material for medical use comprises the following steps:

[0033] The first step is to add polyhexamethylene carbonate diol into a flask, introduce nitrogen, heat to 75°C and stir at a uniform speed until it melts, add isophorone diisocyanate, keep warm and stir magnetically for 3 hours to obtain a prepolymer, then add dimethyl carbonate to reduce the viscosity, continue stirring and react for 1 hour, cool to 60°C, add dibutyltin dilaurate and 2,2-bis(hydroxymethyl)propionic acid, continue stirring and react for 3 hours to obtain a polyurethane resin, and control the amount ratio of polyhexamethylene carbonate diol, isophorone diisocyanate, dimethyl carbonate and 2,2-bis(hydroxymethyl)propionic acid to be 12g:4.5mL:28mL:1.8mL, and the amount of dibutyltin dilaurate is 0.2% of the weight of polyhexamethylene carbonate diol;

[0034] The second step is to mix the prepared polyurethane resin and modified barium sulfate and send them into a twin-screw extruder for extrusion and granulation to obtain a sample. The screw speed is controlled to be 100r / min, the extrusion temperature is 195°C, and the weight ratio of the polyurethane resin to the modified barium sulfate is 4:1;

[0035] The third step is to add the prepared sample into tetrahydrofuran, stir at a uniform speed and add heparin, stir for 15 minutes, add 4-dimethylaminopyridine and diisopropylcarbodiimide, stir for 4 hours in an ice-water bath, transfer to room temperature and continue stirring for 4 hours, filter, and vacuum dry to obtain a medical thermoplastic polyurethane material, and control the weight ratio of the sample, heparin, 4-dimethylaminopyridine, diisopropylcarbodiimide and tetrahydrofuran to be 15:1:0.1:0.4:25.

[0036] The modified barium sulfate comprises the following steps:

[0037] Step S1, adding barium carbonate to deionized water, stirring magnetically and adding sodium sulfate at 45° C., stirring magnetically for 30 minutes, slowly adding an aqueous solution of polyethyleneimide, stirring evenly and transferring to a reactor, heating to 150° C., keeping the temperature for reaction for 10 hours, filtering after the reaction, washing with deionized water and anhydrous ethanol three times respectively, and drying to obtain pretreated barium sulfate, controlling the weight ratio of barium carbonate, polyethyleneimide and deionized water to be 5 g: 0.144 g: 50 mL, and the molar ratio of barium carbonate to sodium sulfate to be 1: 1;

[0038] The aqueous solution of polyethyleneimide is prepared by mixing polyethyleneimide and deionized water in a dosage ratio of 0.144 g:10 mL.

[0039] Step S2, dispersing the obtained pretreated barium sulfate in anhydrous ethanol, adding hexyl bromide, stirring magnetically and reacting for 12 hours at room temperature, adding methyl iodide and continuing the reaction for 12 hours, washing with deionized water and anhydrous ethanol three times respectively after the reaction, drying at 55° C. to obtain modified barium sulfate, controlling the weight ratio of the pretreated barium sulfate, hexyl bromide and anhydrous ethanol to be 1:10:50, and the molar ratio of methyl iodide and hexyl bromide to be 1:1.

[0040] Example 3

[0041] A production process of a thermoplastic polyurethane material for medical use comprises the following steps:

[0042] The first step is to add polyhexamethylene carbonate diol into a flask, introduce nitrogen, heat to 75°C and stir at a uniform speed until it melts, add isophorone diisocyanate, keep warm and stir magnetically for 3 hours to obtain a prepolymer, then add dimethyl carbonate to reduce the viscosity, continue stirring and react for 1 hour, cool to 60°C, add dibutyltin dilaurate and 2,2-bis(hydroxymethyl)propionic acid, continue stirring and react for 3 hours to obtain a polyurethane resin, and control the amount ratio of polyhexamethylene carbonate diol, isophorone diisocyanate, dimethyl carbonate and 2,2-bis(hydroxymethyl)propionic acid to be 15g:5mL:30mL:2mL, and the amount of dibutyltin dilaurate is 0.3% of the weight of polyhexamethylene carbonate diol;

[0043] The second step is to mix the prepared polyurethane resin and modified barium sulfate and send them into a twin-screw extruder for extrusion and granulation to obtain a sample. The screw speed is controlled to be 100r / min, the extrusion temperature is 195°C, and the weight ratio of the polyurethane resin to the modified barium sulfate is 5:1;

[0044] The third step is to add the prepared sample into tetrahydrofuran, stir at a uniform speed and add heparin, stir for 15 minutes, add 4-dimethylaminopyridine and diisopropylcarbodiimide, stir for 4 hours in an ice-water bath, transfer to room temperature and continue stirring for 4 hours, filter, and vacuum dry to obtain a medical thermoplastic polyurethane material, and control the weight ratio of the sample, heparin, 4-dimethylaminopyridine, diisopropylcarbodiimide and tetrahydrofuran to be 20:1:0.2:0.5:30.

[0045] The modified barium sulfate comprises the following steps:

[0046] Step S1, adding barium carbonate to deionized water, stirring magnetically at 45°C and adding sodium sulfate, stirring magnetically for 30 minutes, slowly adding an aqueous solution of polyethyleneimide, stirring evenly and transferring to a reactor, heating to 150°C, and keeping the temperature for reaction for 10 hours. After the reaction is completed, filtering, washing with deionized water and anhydrous ethanol three times respectively, and drying to obtain pretreated barium sulfate, wherein the weight ratio of barium carbonate, polyethyleneimide and deionized water is controlled to be 5.02 g: 0.144 g: 50 mL, and the molar ratio of barium carbonate to sodium sulfate is 1: 1;

[0047] The aqueous solution of polyethyleneimide is prepared by mixing polyethyleneimide and deionized water in a dosage ratio of 0.144 g:10 mL.

[0048] Step S2, dispersing the obtained pretreated barium sulfate in anhydrous ethanol, adding hexyl bromide, stirring magnetically and reacting for 12 hours at room temperature, adding methyl iodide and continuing the reaction for 12 hours, washing with deionized water and anhydrous ethanol three times respectively after the reaction, drying at 55° C. to obtain modified barium sulfate, controlling the weight ratio of the pretreated barium sulfate, hexyl bromide and anhydrous ethanol to be 1:10:50, and the molar ratio of methyl iodide and hexyl bromide to be 1:1.

[0049] Biological tests were performed on the medical thermoplastic polyurethane materials prepared in Examples 1-3;

[0050] 1. Acute systemic toxicity

[0051] This test was conducted in accordance with the national standard GB / T16886.112011 "Biological Evaluation of Medical Devices Part 11: Systemic Toxicity Test" method, and the 0.9% sodium chloride injection (SC) and cottonseed oil (CSO) sample test solutions of the test samples were subjected to acute systemic toxicity tests in mice.

[0052] The test samples were extracted with SC and CSO and given to the test animals by intraperitoneal injection (IP); the status of all animals and the number of dead animals were observed and recorded immediately, 4h, 24h, 48h and 72h after injection. All animals were weighed and recorded 24h, 48h and 72h after injection.

[0053] Under the test conditions, no animals in the test group and the control group died, no test mice showed any symptoms of poisoning, and the weight of the mice increased. The test results show that the thermoplastic polyurethane material test solution of Examples 1-3 has no acute systemic effect on the test mice.

[0054] 2. Cytotoxicity test

[0055] This test uses in vitro cell culture method to conduct toxicological risk assessment. This test is carried out according to the MTT method of the national standard GB / T16886.5-2017 "Biological Evaluation of Medical Devices Part 5: In Vitro Cytotoxicity Test".

[0056] The sample test solution, the extracts of the negative control and positive control, and the medium control were placed in 6 wells of a cell culture plate cultured with L929 mouse fibroblasts, and cultured in a 5% CO2, 37°C cell culture incubator. After 24 hours, the cell morphological changes of the test sample group, negative control group, positive control group, and medium control group after culture were observed under a microscope, and the cell survival rate of each test sample group, negative control group, positive control group relative to the medium control group was determined by the MTT method.

[0057] Under the test conditions, the cell survival rate of the thermoplastic polyurethane material test solution of Examples 1-3 is in the range of 81-90%, and there is no potential cytotoxicity. (Reference standard: if the survival rate is less than 70%, it is potentially toxic)

[0058] 3. Skin sensitization test

[0059] This test was conducted in accordance with the national standard GB / T16886.10-2017 "Biological Evaluation of Medical Devices Part 10: Irritation and Skin Sensitization Tests". The maximum skin sensitization dose test was conducted on the test samples of 0.9% sodium chloride injection (SC) and cottonseed oil (CSO) test solution to evaluate the potential of the test samples to cause skin sensitization reactions in guinea pigs under the test conditions.

[0060] The test samples were extracted using SC and CSO. Each test solution was intradermally injected and fixed on the shaved area on the back of the guinea pigs in the test group to induce skin sensitization; after the induction period, the filter paper soaked with the test solution was fixed on the shaved area on the abdomen of the animals in the test group for 24 hours. The skin conditions of all animals at the stimulating site were observed and recorded 24 hours and 48 hours after the filter paper was removed, and described and graded according to the Magnusson and Kligman grading standards. The control group animals were operated in the same way.

[0061] Under the test conditions, the thermoplastic polyurethane material test solutions of Examples 1-3 did not cause skin allergy in guinea pigs.

[0062] 4. Intradermal reaction test

[0063] This test uses rabbits for intradermal reaction tests to evaluate the potential of the test samples to produce irritation reactions under test conditions. This test is conducted in accordance with the provisions of the national standard GB / T16886.10-2017 "Biological Evaluation of Medical Devices Part 10: Irritation and Skin Sensitization Tests".

[0064] The test samples were extracted with 0.9% sodium chloride injection (SC) and cotton wool oil (CSO), and blank control solutions without test samples were prepared in the same way. The test solutions and blank control solutions were injected intradermally on both sides of the spine of home rabbits. The erythema and edema at the injection site were scored at (24±2)h, (48±2)h and (72±2)h after injection, and the final scores of intradermal reactions of the test samples and the corresponding blank controls were calculated.

[0065] Under the test conditions, the final scores of the thermoplastic polyurethane materials SC and CSO test solutions of Examples 1-3 were all less than 1.0, meeting the test requirements.

[0066] Comparative Example 1

[0067] Compared with Example 3, this comparative example uses 1,4-butanediol instead of 2,2-bis(hydroxymethyl)propionic acid as the chain extender, and the rest is the same as Example 3.

[0068] Comparative Example 2

[0069] Compared with Example 3, this comparative example does not perform modification treatment on barium sulfate, and the rest is the same as Example 3.

[0070] Comparative Example 3

[0071] This comparative example is the method disclosed in the embodiment of Chinese invention patent CN201811614127.7 in which heparin is coated on the surface of TPU as a coating.

[0072] The properties of the polyurethane materials prepared in Examples 1-3 and Comparative Examples 1-3 were tested, and the results are shown in Table 1 below:

[0073] Anticoagulation test: including activated partial thromboplastin time (APTT) and thrombin time (TT).

[0074] First, cut the sample into 0.5X0.5 cm 2 Take fresh whole blood from healthy rats and centrifuge it at 4℃ for 15 minutes (2500rpm) to obtain the supernatant, i.e. platelet-poor plasma (PPP); the coagulation time test method is carried out according to the requirements of the corresponding kit, and the specific process is as follows:

[0075] (1) APTT test

[0076] Place the material in a 1.5 mL centrifuge tube, add 100 μL PPP, and incubate at 37°C for 30 minutes. Then take 50 μL of the incubated PPP, add 50 μL APTT reagent and mix well, incubate at 37°C for 3 minutes, immediately add 50 μL 0.025 M CaCl2 solution, mix well and count, and record the plasma coagulation time as APTT.

[0077] (2)TT test

[0078] The material was placed in a 1.5 mL centrifuge tube, 150 μL PPP was added, and the mixture was incubated at 37°C for 30 minutes. Then 100 μL of the incubated PPP was aspirated, 100 μL TT reagent was added, and the plasma coagulation time was recorded as TT after incubation for 3 minutes.

[0079] Antibacterial test: Gram-positive bacteria: Staphylococcus aureus; Gram-negative bacteria: Escherichia coli were selected as model bacteria. The operation method is as follows: Staphylococcus aureus and Escherichia coli were activated and amplified, and then diluted to a concentration of 5×10 5 CFU / mL bacterial suspension, use a sterile pipette to take 200μL of the bacterial suspension and evenly spread it on the surface of each sample, and culture it at 37℃ for 24h; then use an equal volume of culture medium to blow off the bacteria on the surface of the sample, culture it at 37℃ for another 8h, spread it on the plate after dilution, count the number of colonies in each group of samples and calculate the inhibition rate.

[0080] Table 1

[0081]

[0082] It can be seen from Table 1 above that the polyurethane materials prepared in Examples 1-3 of the present invention have good anticoagulant and antibacterial properties.

[0083] The above contents are merely examples and explanations of the concept of the present invention. The technicians in this technical field may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the concept of the invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.

Claims

1. A production process of a thermoplastic polyurethane material for medical use, characterized in that: The steps include: The first step is to add polyhexamethylene carbonate diol into a flask, introduce nitrogen, heat to 75°C and stir at a uniform speed until it melts, add isophorone diisocyanate, keep warm and stir magnetically for 3 hours to obtain a prepolymer, then add dimethyl carbonate, continue stirring and react for 1 hour, cool to 60°C, add dibutyltin dilaurate and 2,2-bis(hydroxymethyl)propionic acid, continue stirring and react for 3 hours to obtain a polyurethane resin; The second step is to mix the prepared polyurethane resin and modified barium sulfate and send them into a twin-screw extruder for extrusion and granulation to prepare a sample; Step 3: Add the prepared sample to tetrahydrofuran, stir at a uniform speed and add heparin, stir for 15 minutes, add 4-dimethylaminopyridine and diisopropylcarbodiimide, stir for 4 hours in an ice-water bath, transfer to room temperature and continue stirring for 4 hours, filter, and vacuum dry to obtain a medical thermoplastic polyurethane material; The modified barium sulfate comprises the following steps: Step S1, adding barium carbonate to deionized water, stirring magnetically at 45°C and adding sodium sulfate, stirring magnetically for 30 minutes, slowly adding an aqueous solution of polyethyleneimine, stirring evenly and transferring to a reactor, heating to 150°C, keeping the temperature for reaction for 10 hours, filtering after the reaction, washing with deionized water and anhydrous ethanol three times respectively, and drying to obtain pretreated barium sulfate; Step S2, dispersing the obtained pretreated barium sulfate in anhydrous ethanol, adding hexyl bromide, stirring magnetically and reacting for 12 hours at room temperature, adding iodomethane and continuing the reaction for 12 hours, washing with deionized water and anhydrous ethanol three times respectively after the reaction, and drying at 55° C. to obtain modified barium sulfate.

2. The production process of a medical thermoplastic polyurethane material according to claim 1, characterized in that: In the first step, the dosage ratio of polyhexamethylene carbonate diol, isophorone diisocyanate, dimethyl carbonate and 2,2-bis(hydroxymethyl)propionic acid is controlled to be 10-15 g: 4-5 mL: 25-30 mL: 1.5-2 mL, and the dosage of dibutyltin dilaurate is 0.1-0.3% of the weight of polyhexamethylene carbonate diol.

3. The production process of a medical thermoplastic polyurethane material according to claim 1, characterized in that: In the second step, the screw speed is controlled to be 100 r / min, the extrusion temperature is 195° C., and the weight ratio of the polyurethane resin to the modified barium sulfate is 4-5:

1.

4. The production process of a medical thermoplastic polyurethane material according to claim 1, characterized in that: In the third step, the weight ratio of the sample, heparin, 4-dimethylaminopyridine, diisopropylcarbodiimide and tetrahydrofuran is controlled to be 10-20:1:0.1-0.2:0.3-0.5:20-30.

5. The production process of a medical thermoplastic polyurethane material according to claim 1, characterized in that: In step S1, the weight ratio of barium carbonate, polyethyleneimine and deionized water is controlled to be 4.58-5.02 g: 0.144 g: 50 mL, and the molar ratio of barium carbonate to sodium sulfate is 1:

1.

6. The production process of a medical thermoplastic polyurethane material according to claim 1, characterized in that: The aqueous solution of polyethyleneimine in step S1 is prepared by mixing polyethyleneimine and deionized water in a dosage ratio of 0.144 g:10 mL.

7. The production process of a medical thermoplastic polyurethane material according to claim 1, characterized in that: In step S2, the weight ratio of the pretreated barium sulfate, hexyl bromide and anhydrous ethanol is controlled to be 1:10:50, and the molar ratio of methyl iodide and hexyl bromide is controlled to be 1:1.